NDA 210493 · Helsinn Hlthcare
Akynzeo
Fosnetupitant Chloride Hydrochloride, Palonosetron Hydrochloride · Intravenous · Substance P/Neurokinin-1 Receptor Antagonist; Serotonin-3 Receptor Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Feb 15, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Apr 19, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
1,200
1,119 serious, 170 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 23, 2026.
AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. Limitations of Use AKYNZEO for injection and AKYNZEO injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Limitations of Use AKYNZEO for injection and AKYNZEO injection...
Mechanism: Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Palonosetron is a 5-HT 3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT 3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. Chemotherapeutic agents produce nausea and vomiting by stimulating the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 19, 2018 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLabelLetterReview
2 products under this application
- AKYNZEO · FOSNETUPITANT CHLORIDE HYDROCHLORIDE EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML); PALONOSETRON HYDROCHLORIDE EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- AKYNZEO · FOSNETUPITANT CHLORIDE HYDROCHLORIDE EQ 235MG BASE/VIAL; PALONOSETRON HYDROCHLORIDE EQ 0.25MG BASE/VIAL · POWDER, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fosnetupitant Chloride" as an intervention, any sponsor and status, largest first.
Helsinn Healthcare SAIndustry
NCT06840769 · 50 participants · Start Jun 17, 2023 · Primary completion Oct 18, 2023
Drug: Fosnetupitant 235 mg solution; Akynzeo solution · For: Healthy Volunteers
Sites: Arzo, Switzerland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea129
- fatigue92
- diarrhoea91
- neutropenia89
- dyspnoea75
- vomiting72
- death68
- pyrexia57
- off label use56
- febrile neutropenia52
- anaemia46
- decreased appetite46
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 9 |
| 2016 | 18 |
| 2017 | 43 |
| 2018 | 75 |
| 2019 | 152 |
| 2020 | 148 |
| 2021 | 188 |
| 2022 | 92 |
| 2023 | 78 |
| 2024 | 113 |
| 2025 | 148 |
| 2026 | 136 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Akynzeo (Fosnetupitant/Palonosetron)
2024 spending
$4.8M
Beneficiaries
1,119
4,375 claims
Per beneficiary
$4,258
$32.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $355,121 |
| 2021 | $228,707 |
| 2022 | $2,419,510 |
| 2023 | $4,508,722 |
| 2024 | $4,764,483 |
Part D: Akynzeo (Netupitant/Palonosetron HCl)
2024 spending
$354K
Beneficiaries
99
341 claims
Per beneficiary
$3,573
$671.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $296,175 |
| 2021 | $398,551 |
| 2022 | $466,394 |
| 2023 | $440,871 |
| 2024 | $353,760 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin.
Yeo W, Lau TK, Kwok CC, et al. · BMJ Support Palliat Care 2022 · Clinical Trial
Sponsor: Helsinn Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.